CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: GRSF1 (ImmuneEditome ID:2926)

1. Gene summary of enriched editing regions for GRSF1

check button Gene summary
Gene informationGene symbol

GRSF1

Gene ID

2926

GeneSynonyms-
GeneCytomap

4q13.3

GeneTypeprotein-coding
GeneDescriptionG-rich sequence factor 1
GeneModificationdate20230517
UniprotIDQ12849;A0A024RD99;H0YAM1;H0YAK1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr4:70816192-70818303:-ENST00000254799.9ENSG00000132463.12GRSF1UTR3AluSz6,AluSx,L1MC,L1ME2z,L1ME4b,AluJb,AluSzchr4:70816192-70818303:-.alignment
chr4:70821657-70822549:-ENST00000505068.4ENSG00000132463.12GRSF1ncRNA_intronicAluSq,AluSxchr4:70821657-70822549:-.alignment
chr4:70821657-70822549:-ENST00000508091.1ENSG00000132463.12GRSF1ncRNA_intronicAluSq,AluSxchr4:70821657-70822549:-.alignment
chr4:70823603-70824292:-ENST00000254799.9ENSG00000132463.12GRSF1splicingAluJr,AluSx1chr4:70823603-70824292:-.alignment
chr4:70823603-70824292:-ENST00000499044.5ENSG00000132463.12GRSF1splicingAluJr,AluSx1chr4:70823603-70824292:-.alignment
chr4:70823603-70824292:-ENST00000502323.4ENSG00000132463.12GRSF1splicingAluJr,AluSx1chr4:70823603-70824292:-.alignment
chr4:70823603-70824292:-ENST00000506453.1ENSG00000132463.12GRSF1splicingAluJr,AluSx1chr4:70823603-70824292:-.alignment
chr4:70823603-70824292:-ENST00000514161.4ENSG00000132463.12GRSF1splicingAluJr,AluSx1chr4:70823603-70824292:-.alignment
chr4:70823603-70824292:-ENST00000545193.4ENSG00000132463.12GRSF1splicingAluJr,AluSx1chr4:70823603-70824292:-.alignment


Top

2. Tumor-specific enriched editing regions for GRSF1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr4:70816192-70818303:-KICHEER3.0700e-04image
ENSG00000132463.12,GRSF1KICHEAG8.1932e-04image
chr4:70816192-70818303:-KIRPEER6.0355e-03image
ENSG00000132463.12,GRSF1KIRPEAG6.1375e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr4:70816192-70818303:-ACCPathEER4.3992e-034.5565e-04-0.4421image
ENSG00000132463.12,GRSF1ACCPathEAG4.3992e-034.5565e-04-0.4421image
chr4:70816192-70818303:-KIRPPathEER1.4861e-021.2510e-020.1709image
ENSG00000132463.12,GRSF1KIRPPathEAG3.4159e-022.1299e-020.1574image
chr4:70816192-70818303:-UVMCliEER1.9523e-021.0708e-020.3327image
ENSG00000132463.12,GRSF1UVMCliEAG1.9523e-021.0708e-020.3327image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000132463.12,GRSF1LAMLEAG3.8871e-024.2221e-031.9406e+01image

Top

3. Enriched editing regions and immune related genes for GRSF1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr4:70816192-70818303:-COADEERENSG00000206650,SNORA70G0.20097.0343e-036.8478e-120.4584imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr4:70816192-70818303:-COADEERENSG00000259318,RP11-454L9.20.24261.3598e-029.8738e-110.4350imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr4:70816192-70818303:-COADEERENSG00000143614,GATAD2B0.22013.0841e-021.8407e-110.4500imageNNNAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr4:70816192-70818303:-COADEERENSG00000265135,MIR56870.11704.3646e-023.3449e-100.4236imageNNNADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr4:70816192-70818303:-GBMEERENSG00000260920,RP1-228H13.5-0.47473.1009e-063.0218e-09-0.4592imageNNNAMacrophages_M0GSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr4:70816192-70818303:-GBMEERENSG00000260296,RP11-395I6.3-0.45501.4853e-053.0922e-07-0.4021imageNNNAT_cells_follicular_helperGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr4:70816192-70818303:-GBMEERENSG00000203668,CHML-0.42855.2972e-053.5155e-07-0.4004imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr4:70816192-70818303:-GBMEERENSG00000198720,ANKRD13B-0.42876.3209e-051.4951e-07-0.4118imageNNNAMonocytesGSVA_HALLMARK_APOPTOSIS
chr4:70816192-70818303:-GBMEERENSG00000232640,RP1-266L20.2-0.41879.9854e-057.9723e-08-0.4199imageNNNAMonocytesGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr4:70816192-70818303:-GBMEERENSG00000135926,TMBIM10.41181.1248e-047.0195e-080.4216imageNNNAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM

More results



Top

4. Enriched editing regions and immune related splicing for GRSF1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000132463.12,GRSF1
COADEAGMEXENSG00000168028.9chr339407640:39407786:39408605:39408724:39410909:39410999:39411648:394117770.29071.1292e-021.3212e-090.4094imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184RPSAEosinophilsGSVA_HALLMARK_P53_PATHWAY
ENSG00000132463.12,GRSF1
COADEAGMEXENSG00000006282.15chr1750550733:50550917:50550997:50551190:50552116:50552180:50554250:505544500.26143.0438e-021.4210e-090.4144imageNALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr4:70816192-70818303:-
COADEERMEXENSG00000168028.9chr339407640:39407786:39408605:39408724:39410909:39410999:39411648:394117770.29428.4992e-031.1190e-100.4338imageNNRPSAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr4:70816192-70818303:-
COADEERMEXENSG00000006282.15chr1750550733:50550917:50550997:50551190:50552116:50552180:50554250:505544500.25513.5064e-024.4267e-110.4483imageNNNAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
ENSG00000132463.12,GRSF1
OVEAGMEXENSG00000115307.12chr274527939:74528006:74528247:74528321:74528735:74528935:74529131:74529282-0.46997.6699e-114.6365e-15-0.4506imageNACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL14;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_ADIPOGENESIS
ENSG00000132463.12,GRSF1
OVEAGMEXENSG00000182240.11chr2141167800:41168575:41226265:41226354:41257157:41257326:41275370:412753810.42656.6900e-091.7852e-120.4097imageNACIN1;ADAR;AIFM1;ALYREF;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FTO;FUS;FXR2;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LIN28;LIN28A;LIN28B;MBNL2;METTL14;METTL3;MOV10;MSI1;NOP56;NOP58;PTBP1;QKI;RANGAP1;RBFOX2;RBM47;RBM5;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIAL1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7BNAMacrophages_M2GSVA_HALLMARK_HEME_METABOLISM
ENSG00000132463.12,GRSF1
OVEAGIRENSG00000103266.6chr16681792:681880:682019:682076-0.42538.2703e-094.4019e-13-0.4198imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL14;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184STUB1Macrophages_M2GSVA_HALLMARK_HEME_METABOLISM
ENSG00000132463.12,GRSF1
OVEAGMEXENSG00000134291.7chr1247964280:47964423:47965281:47965345:47967207:47967261:47968132:479681710.41242.1845e-085.7282e-120.4010imageNAIFM1;ALYREF;AUH;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RC3H1;RNF219;RTCB;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDF1;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_HEME_METABOLISM
ENSG00000132463.12,GRSF1
OVEAGMEXENSG00000075624.9chr75528149:5528185:5528280:5529376:5529387:5529400:5529534:5529663-0.41382.3348e-082.5747e-12-0.4070imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NANeutrophilsGSVA_HALLMARK_HEME_METABOLISM
chr4:70816192-70818303:-
OVEERMEXENSG00000075624.9chr75528149:5528185:5528280:5529376:5529387:5529400:5529534:5529663-0.41852.6842e-081.9204e-12-0.4112imageNNNANeutrophilsGSVA_HALLMARK_HEME_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for GRSF1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr4:70816192-70818303:-ACCEERMast_cells_resting6.2604e-030.3491image
ENSG00000132463.12,GRSF1ACCEAGMast_cells_resting6.2604e-030.3491image
chr4:70816192-70818303:-BLCAEERMacrophages_M13.0588e-020.1436image
ENSG00000132463.12,GRSF1BLCAEAGB_cells_memory2.7274e-02-0.1431image
chr4:70816192-70818303:-CESCEERB_cells_memory3.0007e-02-0.1641image
ENSG00000132463.12,GRSF1CESCEAGB_cells_memory3.2098e-02-0.1612image
chr4:70816192-70818303:-COADEEREosinophils7.0080e-040.2365image
ENSG00000132463.12,GRSF1COADEAGEosinophils3.5698e-030.2036image
chr4:70816192-70818303:-ESCAEERMacrophages_M21.2242e-020.2083image
chr4:70821657-70822549:-ESCAEERNK_cells_activated3.2000e-020.3440image
chr4:70823603-70824292:-ESCAEERMast_cells_activated9.4202e-050.5148image
ENSG00000132463.12,GRSF1ESCAEAGT_cells_CD4_memory_resting1.2496e-02-0.2049image
chr4:70816192-70818303:-GBMEERT_cells_follicular_helper8.7090e-03-0.2128image
ENSG00000132463.12,GRSF1GBMEAGT_cells_follicular_helper1.1422e-02-0.2054image
chr4:70816192-70818303:-HNSCEEREosinophils1.0090e-020.1621image
ENSG00000132463.12,GRSF1HNSCEAGEosinophils1.0350e-020.1616image
ENSG00000132463.12,GRSF1KICHEAGT_cells_CD4_memory_activated5.1640e-030.3509image
chr4:70816192-70818303:-KIRCEERMonocytes5.5581e-03-0.1494image
ENSG00000132463.12,GRSF1KIRCEAGMonocytes4.7732e-03-0.1512image
chr4:70816192-70818303:-KIRPEERT_cells_CD4_memory_activated2.4617e-020.1475image
ENSG00000132463.12,GRSF1LAMLEAGMonocytes4.9603e-020.1959image
chr4:70816192-70818303:-LGGEERT_cells_regulatory_(Tregs)4.8755e-020.0869image
ENSG00000132463.12,GRSF1LGGEAGT_cells_regulatory_(Tregs)4.8792e-020.0869image
chr4:70816192-70818303:-LIHCEERNK_cells_activated3.2417e-02-0.2152image
ENSG00000132463.12,GRSF1LIHCEAGNK_cells_activated3.3059e-02-0.2144image
chr4:70816192-70818303:-LUADEERMacrophages_M14.5470e-020.1186image
ENSG00000132463.12,GRSF1LUADEAGMacrophages_M03.0675e-020.1265image
chr4:70816192-70818303:-LUSCEERNeutrophils3.0961e-02-0.1368image
ENSG00000132463.12,GRSF1LUSCEAGNeutrophils3.1810e-02-0.1337image
chr4:70816192-70818303:-MESOEERB_cells_naive4.7740e-03-0.3718image
ENSG00000132463.12,GRSF1MESOEAGB_cells_naive4.4743e-03-0.3744image
chr4:70816192-70818303:-OVEERT_cells_CD86.0757e-030.1666image
chr4:70821657-70822549:-OVEERPlasma_cells5.1228e-03-0.4978image
ENSG00000132463.12,GRSF1OVEAGMacrophages_M23.9598e-030.1739image
chr4:70816192-70818303:-PAADEERDendritic_cells_resting1.1893e-020.2435image
ENSG00000132463.12,GRSF1PAADEAGDendritic_cells_resting1.1933e-020.2434image
chr4:70816192-70818303:-READEEREosinophils1.7492e-020.2813image
ENSG00000132463.12,GRSF1READEAGEosinophils1.5766e-020.2836image
ENSG00000132463.12,GRSF1SARCEAGMacrophages_M24.8421e-020.1426image
ENSG00000132463.12,GRSF1SKCMEAGMacrophages_M14.7361e-02-0.0982image
chr4:70821657-70822549:-STADEERNK_cells_resting2.0231e-020.2660image
chr4:70823603-70824292:-STADEERT_cells_regulatory_(Tregs)6.9404e-03-0.2996image
ENSG00000132463.12,GRSF1STADEAGT_cells_CD4_memory_activated3.4337e-020.1172image
chr4:70816192-70818303:-TGCTEERMacrophages_M22.2314e-03-0.3236image
ENSG00000132463.12,GRSF1TGCTEAGMacrophages_M22.2035e-03-0.3240image
chr4:70816192-70818303:-THCAEERDendritic_cells_activated1.8008e-020.1102image
ENSG00000132463.12,GRSF1THCAEAGDendritic_cells_activated1.9105e-020.1090image
chr4:70816192-70818303:-THYMEERB_cells_naive4.8010e-060.4498image
ENSG00000132463.12,GRSF1THYMEAGB_cells_naive4.5586e-060.4486image
chr4:70816192-70818303:-UCECEERT_cells_follicular_helper3.6291e-020.1930image
chr4:70816192-70818303:-UVMEERNK_cells_activated1.0237e-020.3347image
ENSG00000132463.12,GRSF1UVMEAGNK_cells_activated1.0237e-020.3347image


Top

6. Enriched editing regions and immune gene sets for GRSF1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000132463.12,GRSF1ACCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.7081e-030.3805image
chr4:70816192-70818303:-ACCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.7081e-030.3805image
ENSG00000132463.12,GRSF1BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG5.5981e-050.2581image
chr4:70816192-70818303:-BLCAGSVA_HALLMARK_APICAL_SURFACEEER8.8125e-050.2573image
ENSG00000132463.12,GRSF1BRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.9392e-040.1169image
chr4:70816192-70818303:-BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEER1.1498e-040.1247image
chr4:70816192-70818303:-CESCGSVA_HALLMARK_DNA_REPAIREER1.3369e-03-0.2407image
ENSG00000132463.12,GRSF1CESCGSVA_HALLMARK_DNA_REPAIREAG1.4073e-03-0.2382image
ENSG00000132463.12,GRSF1CHOLGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.1947e-020.3992image
chr4:70816192-70818303:-CHOLGSVA_HALLMARK_MITOTIC_SPINDLEEER3.1947e-020.3992image
chr4:70816192-70818303:-COADGSVA_HALLMARK_DNA_REPAIREER7.5134e-04-0.2352image
ENSG00000132463.12,GRSF1COADGSVA_HALLMARK_DNA_REPAIREAG1.0321e-03-0.2287image
chr4:70823603-70824292:-ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEER2.9487e-02-0.3021image
chr4:70816192-70818303:-ESCAGSVA_HALLMARK_MYOGENESISEER1.6432e-020.1996image
ENSG00000132463.12,GRSF1ESCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.4493e-020.1849image
chr4:70816192-70818303:-GBMGSVA_HALLMARK_P53_PATHWAYEER7.9711e-060.3545image
ENSG00000132463.12,GRSF1GBMGSVA_HALLMARK_P53_PATHWAYEAG8.6948e-060.3531image
chr4:70816192-70818303:-HNSCGSVA_HALLMARK_P53_PATHWAYEER5.0225e-030.1766image
ENSG00000132463.12,GRSF1HNSCGSVA_HALLMARK_P53_PATHWAYEAG5.5314e-030.1746image
ENSG00000132463.12,GRSF1KICHGSVA_HALLMARK_APICAL_SURFACEEAG3.3731e-02-0.2701image
chr4:70816192-70818303:-KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.9406e-020.1262image
ENSG00000132463.12,GRSF1KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.7527e-020.1275image
ENSG00000132463.12,GRSF1KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG8.1408e-030.1730image
chr4:70816192-70818303:-KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER9.3693e-030.1703image
ENSG00000132463.12,GRSF1LAMLGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG6.1222e-030.2710image
ENSG00000132463.12,GRSF1LGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.0656e-04-0.1584image
chr4:70816192-70818303:-LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER3.0751e-04-0.1584image
chr4:70816192-70818303:-LIHCGSVA_HALLMARK_MTORC1_SIGNALINGEER1.2403e-020.2505image
ENSG00000132463.12,GRSF1LIHCGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.4022e-020.2462image
ENSG00000132463.12,GRSF1LUADGSVA_HALLMARK_HYPOXIAEAG3.2451e-030.1717image
chr4:70816192-70818303:-LUADGSVA_HALLMARK_HYPOXIAEER2.8349e-030.1762image
ENSG00000132463.12,GRSF1MESOGSVA_HALLMARK_DNA_REPAIREAG1.8284e-030.4074image
chr4:70816192-70818303:-MESOGSVA_HALLMARK_DNA_REPAIREER1.8381e-030.4073image
chr4:70816192-70818303:-OVGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.5561e-080.3357image
ENSG00000132463.12,GRSF1OVGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG4.2139e-090.3461image
chr4:70821657-70822549:-OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.9314e-030.5244image
chr4:70823603-70824292:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.6561e-030.5801image
chr4:70816192-70818303:-PAADGSVA_HALLMARK_PEROXISOMEEER8.7438e-030.2535image
ENSG00000132463.12,GRSF1PAADGSVA_HALLMARK_PEROXISOMEEAG8.6902e-030.2537image
chr4:70816192-70818303:-PCPGGSVA_HALLMARK_G2M_CHECKPOINTEER1.0953e-030.2770image
ENSG00000132463.12,GRSF1PCPGGSVA_HALLMARK_G2M_CHECKPOINTEAG1.0953e-030.2770image
chr4:70816192-70818303:-PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER6.8610e-050.1895image
ENSG00000132463.12,GRSF1PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.2385e-050.2058image
ENSG00000132463.12,GRSF1READGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.5697e-020.2363image
chr4:70816192-70818303:-SARCGSVA_HALLMARK_HYPOXIAEER1.5475e-030.2275image
ENSG00000132463.12,GRSF1SARCGSVA_HALLMARK_HYPOXIAEAG1.3947e-030.2290image
ENSG00000132463.12,GRSF1SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.0004e-030.1623image
chr4:70816192-70818303:-SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.7477e-030.1551image
chr4:70821657-70822549:-STADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER8.1287e-030.3015image
ENSG00000132463.12,GRSF1STADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG2.4523e-050.2314image
chr4:70816192-70818303:-STADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER8.8554e-060.2463image
chr4:70816192-70818303:-TGCTGSVA_HALLMARK_NOTCH_SIGNALINGEER6.8500e-04-0.3571image
ENSG00000132463.12,GRSF1TGCTGSVA_HALLMARK_NOTCH_SIGNALINGEAG6.7403e-04-0.3576image
ENSG00000132463.12,GRSF1THCAGSVA_HALLMARK_G2M_CHECKPOINTEAG6.5057e-060.2080image
chr4:70816192-70818303:-THCAGSVA_HALLMARK_G2M_CHECKPOINTEER4.0477e-060.2130image
ENSG00000132463.12,GRSF1THYMGSVA_HALLMARK_E2F_TARGETSEAG7.3253e-09-0.5484image
chr4:70816192-70818303:-THYMGSVA_HALLMARK_E2F_TARGETSEER1.8659e-09-0.5685image
ENSG00000132463.12,GRSF1UCSGSVA_HALLMARK_MYOGENESISEAG4.3911e-02-0.2953image
chr4:70816192-70818303:-UCSGSVA_HALLMARK_MYOGENESISEER4.2717e-02-0.2969image
ENSG00000132463.12,GRSF1UVMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG4.8002e-030.3654image
chr4:70816192-70818303:-UVMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER4.8002e-030.3654image


Top

7. Enriched editing regions and drugs for GRSF1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000132463.12,GRSF1ACCCI.1040EAG3.2102e-03-0.3744image
chr4:70816192-70818303:-ACCCI.1040EER3.2102e-03-0.3744image
chr4:70816192-70818303:-BLCAImatinibEER2.8662e-04-0.2386image
ENSG00000132463.12,GRSF1BLCAIPA.3EAG3.8133e-040.2284image
chr4:70816192-70818303:-BRCAKIN001.135EER4.0413e-04-0.1144image
ENSG00000132463.12,GRSF1BRCAKIN001.135EAG5.6768e-04-0.1113image
chr4:70816192-70818303:-CESCLenalidomideEER5.1460e-03-0.2106image
ENSG00000132463.12,GRSF1CESCLenalidomideEAG6.0438e-03-0.2056image
chr4:70816192-70818303:-COADCCT007093EER3.1667e-05-0.2883image
ENSG00000132463.12,GRSF1COADCCT007093EAG5.3271e-05-0.2797image
chr4:70823603-70824292:-ESCALapatinibEER1.0864e-02-0.3538image
chr4:70821657-70822549:-ESCAFH535EER1.7209e-030.4857image
ENSG00000132463.12,GRSF1ESCAGemcitabineEAG1.1676e-020.2068image
chr4:70816192-70818303:-ESCAAICAREER1.1205e-02-0.2108image
chr4:70816192-70818303:-GBMAG.014699EER4.8096e-050.3245image
ENSG00000132463.12,GRSF1GBMAG.014699EAG4.5959e-050.3253image
chr4:70816192-70818303:-HNSCEHT.1864EER1.2573e-040.2397image
ENSG00000132463.12,GRSF1HNSCEHT.1864EAG1.2380e-040.2399image
ENSG00000132463.12,GRSF1KICHEHT.1864EAG1.6077e-020.3046image
chr4:70816192-70818303:-KICHEHT.1864EER9.0826e-030.3314image
chr4:70816192-70818303:-KIRCCCT007093EER2.6572e-020.1198image
ENSG00000132463.12,GRSF1KIRCLapatinibEAG3.2714e-020.1148image
chr4:70816192-70818303:-KIRPGW.441756EER2.4052e-05-0.2735image
ENSG00000132463.12,GRSF1KIRPGW.441756EAG1.5901e-05-0.2786image
ENSG00000132463.12,GRSF1LAMLBMS.536924EAG4.2392e-02-0.2024image
ENSG00000132463.12,GRSF1LGGBX.795EAG1.0704e-070.2316image
chr4:70816192-70818303:-LGGBX.795EER1.0711e-070.2316image
ENSG00000132463.12,GRSF1LUADGSK269962AEAG4.1437e-03-0.1673image
chr4:70816192-70818303:-LUADGefitinibEER2.2658e-03-0.1808image
chr4:70816192-70818303:-LUSCABT.263EER1.1549e-040.2419image
ENSG00000132463.12,GRSF1LUSCABT.263EAG2.5221e-040.2260image
ENSG00000132463.12,GRSF1MESOGDC0941EAG1.9605e-030.4050image
chr4:70816192-70818303:-MESOGDC0941EER2.0676e-030.4031image
chr4:70821657-70822549:-OVCCT018159EER1.6316e-040.6351image
ENSG00000132463.12,GRSF1OVAG.014699EAG8.9656e-050.2348image
chr4:70823603-70824292:-OVFH535EER2.8435e-030.6052image
chr4:70816192-70818303:-OVAG.014699EER3.8016e-050.2479image
chr4:70816192-70818303:-PAADBIBW2992EER2.9761e-03-0.2858image
ENSG00000132463.12,GRSF1PAADBIBW2992EAG2.9540e-03-0.2861image
chr4:70816192-70818303:-PCPGAMG.706EER1.3072e-020.2123image
ENSG00000132463.12,GRSF1PCPGAMG.706EAG1.3072e-020.2123image
ENSG00000132463.12,GRSF1PRADGNF.2EAG1.4719e-03-0.1508image
chr4:70816192-70818303:-PRADAZD.0530EER1.0574e-03-0.1572image
chr4:70816192-70818303:-READMG.132EER2.2624e-04-0.4243image
ENSG00000132463.12,GRSF1READFH535EAG7.3178e-03-0.3136image
chr4:70816192-70818303:-SARCLFM.A13EER1.6615e-03-0.2261image
ENSG00000132463.12,GRSF1SARCLFM.A13EAG1.9381e-03-0.2223image
chr4:70816192-70818303:-SKCMGSK269962AEER3.7879e-04-0.1766image
ENSG00000132463.12,GRSF1SKCMGSK269962AEAG3.8913e-04-0.1757image
chr4:70823603-70824292:-STADEHT.1864EER4.4728e-020.2251image
chr4:70816192-70818303:-STADAZ628EER8.5150e-05-0.2185image
ENSG00000132463.12,GRSF1STADAZ628EAG6.0188e-05-0.2203image
chr4:70816192-70818303:-TGCTDocetaxelEER1.5824e-040.3942image
ENSG00000132463.12,GRSF1TGCTDocetaxelEAG1.5523e-040.3946image
chr4:70816192-70818303:-THCAAICAREER6.2610e-10-0.2832image
ENSG00000132463.12,GRSF1THCAAICAREAG5.6613e-10-0.2833image
ENSG00000132463.12,GRSF1THYMBI.D1870EAG2.7567e-120.6379image
chr4:70816192-70818303:-THYMBI.D1870EER7.4819e-120.6306image
ENSG00000132463.12,GRSF1UCECJNK.9LEAG6.6346e-040.3040image
chr4:70816192-70818303:-UCSJNJ.26854165EER4.0453e-030.4116image
ENSG00000132463.12,GRSF1UCSJNJ.26854165EAG3.9959e-030.4121image
ENSG00000132463.12,GRSF1UVMCGP.60474EAG6.8066e-03-0.3516image
chr4:70816192-70818303:-UVMCGP.60474EER6.8066e-03-0.3516image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType